IDEXX to Introduce Applied BioCode’s Innovative Multiplex Technology Across Global Reference Laboratory Network
January 08 2018 - 8:00AM
Business Wire
IDEXX Laboratories, Inc. (NASDAQ: IDXX) and Applied BioCode
(6598:Taipei) today announced that they have entered into an
exclusive global agreement to bring Applied BioCode’s digital
multiplex platform to IDEXX Reference Laboratory customers. IDEXX
anticipates the technology will be commercially available starting
in 2019. Applied BioCode is a California-headquartered diagnostics
company which designs, develops, manufactures, and markets systems
for highly multiplexed assays.
“IDEXX’s market-leading innovation is at the core of our
strategy,” said Jonathan Ayers, Chairman and Chief Executive
Officer of IDEXX Laboratories. “Implementation of Applied BioCode’s
technology supports our vision for margin expansion, and will allow
us to offer customers expanded test menu breadth and menu
customization for each patient sample submitted to IDEXX Reference
Labs in the future. This is consistent with our commitment to
provide the most comprehensive, cost-effective and timely
diagnostic picture for our customers and their patients. This
proprietary technology platform will also likely have applications
in our other animal health diagnostic markets.”
Paired with IDEXX’s proprietary assays and reagents, Applied
BioCode’s technology enables the development of an ultra-high
sensitivity immunoassay platform. Immunoassay is the detection
technology used on platforms such as SNAP for applications as
diverse as vector-borne disease and parasitology, and for both sick
and preventive care uses.
“Applied BioCode is thrilled to introduce our technology to
veterinary medicine with IDEXX, enabling veterinarians to benefit
from our advanced multiplexing capabilities,” said Winston Ho,
President of Applied BioCode. “We look forward to working with the
IDEXX team to implement our platform at its reference
laboratories.”
For more information about IDEXX Reference Laboratories, visit
www.idexx.com.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a member of the S&P 500® Index
and is a leader in pet healthcare innovation, serving practicing
veterinarians around the world with a broad range of diagnostic and
information technology-based products and services. IDEXX products
enhance the ability of veterinarians to provide advanced medical
care, improve staff efficiency and build more economically
successful practices. IDEXX is also a worldwide leader in providing
diagnostic tests and information for livestock and poultry and
tests for the quality and safety of water and milk. Headquartered
in Maine, IDEXX Laboratories employs more than 7,000 people and
offers products to customers in over 175 countries. For more
information about IDEXX, visit: www.idexx.com.
About Applied BioCode
Applied BioCode is a publicly traded diagnostic company that
develops, manufactures, and markets Barcoded Magnetic Beads (BMBs)
and detection systems to facilitate development of highly
multiplexed nucleic acids or protein detection assays. The BMB
technology offers up to 4,096 unique digital barcodes for multiplex
analysis with unmatched decoding accuracy. Our easy-to-use BioCode
systems employ steady state detection without requiring flow
cytometers that are prone to channel blockage or sample cross
contamination. The system is well suited for clinical diagnostic
applications such as detection of infectious pathogens, drug
resistance markers, cancer markers and mutation analysis, as well
as specific applications for the life science research and
agricultural testing markets. For more information, please visit
the company’s website at www.apbiocode.com.
Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the use of words
such as “expects,” “may,” “anticipates,” “intends,” “would,”
“will,” “plans,” “believes,” “estimates,” “should,” and similar
words and expressions. These forward-looking statements are based
on management's current expectations and beliefs, as well as a
number of assumptions concerning future events. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the Company's actual results,
performance or achievements to be materially different from those
expressed or implied by these forward-looking statements. IDEXX
assumes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Readers are advised to review IDEXX’s filings with the
United States Securities and Exchange Commission (which are
available from the SEC’s EDGAR database at www.sec.gov and via
IDEXX’s website at www.idexx.com).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180108005403/en/
Applied BioCodeDr. Winston Z. HoPresident+1 (562) 801-0050
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Mar 2024 to Apr 2024
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Apr 2023 to Apr 2024